EP408 Usefulness of evaluating lymphatic and venous vessel invasion separately in postoperative cervical adenocarcinoma

2019 ◽  
Author(s):  
Y Taira ◽  
Y Shimoji ◽  
T Nakasone ◽  
Y Arakaki ◽  
T Nakamoto ◽  
...  
Keyword(s):  
Cervical Adenocarcinoma ◽  
Vessel Invasion ◽  
Venous Vessel

PROGESTERONE AND PROGESTATIONAL COMPOUNDS IN THE TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA

1965 ◽  
Vol 49 (3) ◽  
pp. 412-426 ◽  
Author(s):  
Per Bergsjö
Keyword(s):  
Endometrial Carcinoma ◽  
Lung Metastases ◽  
Endometrial Adenocarcinoma ◽  
Cervical Adenocarcinoma ◽  
Tumour Tissue ◽  
Pelvic Tumour ◽  
Histological Alterations

ABSTRACT Various doses of progesterone in oil and of two progestational compounds (17α-hydroxy-19-nor-progesterone caproate and 17α-hydroxyprogesterone p-butoxyphenyl propionate) have been given to 15 patients with recurrent and/or metastatic endometrial adenocarcinoma and to one patient with metastatic cervical adenocarcinoma, for periods of up to 27 weeks. Regression of lung metastases was noted in 4 of 13 patients, softening of pelvic tumour in 2 of 4, and histological alterations of tumour tissue in 4 of 5 patients. In the patient with metastases from a cervical adenocarcinoma, the disease progressed during the treatment. The significance of the observations is discussed.

Current Management of In Situ and Invasive Cervical Adenocarcinoma

2005 ◽  
Vol 1 (3) ◽  
pp. 185-196
Author(s):  
John Schorge ◽  
Shawna Bull ◽  
Jayanthi Lea
Keyword(s):  
Cervical Adenocarcinoma ◽  
Current Management

New Hybrid Scaffolds Based on Carbazole-Chalcones as Potent Anticancer Agents

2020 ◽  
Vol 20 ◽  
Author(s):  
Faisal Rashid ◽  
Sumera Zaib ◽  
Aliya Ibrar ◽  
Syeda Abida Ejaz ◽  
Aamer Saeed ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Hela Cells ◽  
Cervical Adenocarcinoma ◽  
G1 Arrest ◽  
Human Breast ◽  
Caspase 9 ◽  
Flow Cytometric ◽  
Pharmacodynamic Profile ◽  
Microscopic Studies ◽  
Mcf 7

Background and Objectives: Despite various technological advances for the treatment of cancer, the identification of new chemical entities with potent anticancer effects remain an indispensable requirement of the time due to multi-drug resistance exhibited by previously developed anticancer drugs. Particularly, the hybrid drugs incorporating two individual bioactive pharmacophores present medicinally important structural leads, thus improving the pharmacodynamic profile of the drug molecules. The antiproliferative and pro-apoptotic activity of the carbazole-chalcone hybrids on human breast and cervical cancer cells will be examined. Materials and Methods: To overcome such complications, in the current study, we evaluated the cytotoxic effects of carbazole-chalcone hybrids on human breast adenocarcinoma (MCF-7), cervical adenocarcinoma (HeLa) cells and normal cells i.e., baby hamster kidney cells (BHK-21) using MTT (dimethyl-2-thiazolyl-2,5-diphenyl-2H-tetrazolium bromide) assay. The mechanistic studies were performed on potent compound 4g by fluorescent microscopic studies, release of lactate dehydrogenase (LDH) and mitochondrial membrane potential, activation of caspase-9 and -3 and flow cytometric analysis. Results: As revealed by MTT assay, compound 4g was identified as the most potent derivative among the tested series with IC50 values of 5.64 and 29.15 μM against HeLa and MCF-7 cells, respectively. The results were compared with cisplatin. Fluorescent microscopic studies using 4′,6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) staining confirmed the occurrence of apoptosis in HeLa cells treated with the most active compound 4g. Moreover, compound 4g also triggered the release of lactate dehydrogenase (LDH) in treated HeLa and MCF-7 cells while a luminescence assay displayed a remarkable increase in the activity of caspase-9 and -3. Moreover, flow cytometric results revealed that compound 4g caused G0/G1 arrest in the treated HeLa cells. Conclusion: Our results demonstrated that the compound 4g possesses chemotherapeutic properties against breast cancer and cervical adenocarcinoma cells, thus warranting further research to test the anticancer efficacy of this compound at clinical level.

Remission of metastatic cervical adenocarcinoma with weekly paclitaxel

2001 ◽  
Vol 11 (2) ◽  
pp. 167-168 ◽  
Author(s):  
S. Ota ◽  
T. Sugiyama ◽  
K. Ushijima ◽  
K. Fujiyoshi ◽  
K. Komai ◽  
...  
Keyword(s):  
Cervical Adenocarcinoma ◽  
Weekly Paclitaxel

Gastric-type cervical adenocarcinoma with squamous differentiation: buried in adenosquamous carcinomas?

2021 ◽  
Author(s):  
Hiroshi Yoshida ◽  
Tomoaki Naka ◽  
Mayumi Kobayashi-Kato ◽  
Nao Kikkawa ◽  
Yasuhito Tanase ◽  
...  
Keyword(s):  
Cervical Adenocarcinoma ◽  
Squamous Differentiation ◽  
Gastric Type

scholarly journals Genomic alterations caused by HPV integration in a cohort of Chinese endocervical adenocarcinomas

2021 ◽  
Author(s):  
Wenhui Li ◽  
Wanjun Lei ◽  
Xiaopei Chao ◽  
Xiaochen Song ◽  
Yalan Bi ◽  
...  
Keyword(s):  
Copy Number ◽  
Somatic Mutations ◽  
Hpv Infection ◽  
Copy Number Variations ◽  
Cervical Adenocarcinoma ◽  
Structural Variations ◽  
Driver Genes ◽  
Genetic Changes ◽  
Genomic Changes ◽  
Whole Exome

AbstractThe association between human papillomavirus (HPV) integration and relevant genomic changes in uterine cervical adenocarcinoma is poorly understood. This study is to depict the genomic mutational landscape in a cohort of 20 patients. HPV+ and HPV− groups were defined as patients with and without HPV integration in the host genome. The genetic changes between these two groups were described and compared by whole-genome sequencing (WGS) and whole-exome sequencing (WES). WGS identified 2916 copy number variations and 743 structural variations. WES identified 6113 somatic mutations, with a mutational burden of 2.4 mutations/Mb. Six genes were predicted as driver genes: PIK3CA, KRAS, TRAPPC12, NDN, GOLGA6L4 and BAIAP3. PIK3CA, NDN, GOLGA6L4, and BAIAP3 were recognized as significantly mutated genes (SMGs). HPV was detected in 95% (19/20) of patients with cervical adenocarcinoma, 7 of whom (36.8%) had HPV integration (HPV+ group). In total, 1036 genes with somatic mutations were confirmed in the HPV+ group, while 289 genes with somatic mutations were confirmed in the group without HPV integration (HPV− group); only 2.1% were shared between the two groups. In the HPV+ group, GOLGA6L4 and BAIAP3 were confirmed as SMGs, while PIK3CA, NDN, KRAS, FUT1, and GOLGA6L64 were identified in the HPV− group. ZDHHC3, PKD1P1, and TGIF2 showed copy number amplifications after HPV integration. In addition, the HPV+ group had significantly more neoantigens. HPV integration rather than HPV infection results in different genomic changes in cervical adenocarcinoma.

Sign in / Sign up

Export Citation Format

Share Document